Targeting GM-CSF in inflammatory diseases
- Author(s)
- Wicks, IP; Roberts, AW;
- Details
- Publication Year 2016-01,Volume 12,Issue #1,Page 37-48
- Journal Title
- Nat Rev Rheumatol
- Publication Type
- Journal Article
- Abstract
- Granulocyte-macrophage colony stimulating factor (GM-CSF) is a growth factor first identified as an inducer of differentiation and proliferation of granulocytes and macrophages derived from haematopoietic progenitor cells. Later studies have shown that GM-CSF is involved in a wide range of biological processes in both innate and adaptive immunity, with its production being tightly linked to the response to danger signals. Given that the functions of GM-CSF span multiple tissues and biological processes, this cytokine has shown potential as a new and important therapeutic target in several autoimmune and inflammatory disorders - particularly in rheumatoid arthritis. Indeed, GM-CSF was one of the first cytokines detected in human synovial fluid from inflamed joints. Therapies that target GM-CSF or its receptor have been tested in preclinical studies with promising results, further supporting the potential of targeting the GM-CSF pathway. In this Review, we discuss our expanding view of the biology of GM-CSF, outline what has been learnt about GM-CSF from studies of animal models and human diseases, and summarize the results of early phase clinical trials evaluating GM-CSF antagonism in inflammatory disorders.
- Publisher
- NPG
- Research Division(s)
- Inflammation; Cancer And Haematology
- PubMed ID
- 26633290
- Publisher's Version
- https://doi.org/10.1038/nrrheum.2015.161
- NHMRC Grants
- NHMRC/1023407, NHMRC/107956, NHMRC/1016647,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2015-12-10 11:27:51
Last Modified: 2016-01-13 10:15:47